Terms: = Pancreatic cancer AND CEACAM5, CEA
1295 results:
1. Performance of Intracystic Glucose Measurement for the Characterization of pancreatic Cystic Lesions.
Ribeiro T; Lopes S; Moutinho-Ribeiro P; Macedo G; Vilas-Boas F
J Gastrointestin Liver Dis; 2024 Mar; 33(1):74-78. PubMed ID: 38554431
[TBL] [Abstract] [Full Text] [Related]
2. Neutrophil Gelatinase-Associated Lipocalin for the Differentiation of Mucinous pancreatic Cystic Lesions.
Olar MP; Iacobescu M; Bolboacă SD; Pojoga C; Moșteanu O; Seicean R; Rusu I; Banc O; Iuga CA; Seicean A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542201
[TBL] [Abstract] [Full Text] [Related]
3. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.
Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H
Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630
[TBL] [Abstract] [Full Text] [Related]
4. Development of a Serum-Based MicroRNA Signature for Early Detection of pancreatic cancer: A Multicenter Cohort Study.
Huang J; Gao G; Ge Y; Liu J; Cui H; Zheng R; Wang J; Wang S; Go VL; Hu S; Liu Y; Yang M; Sun Y; Shang D; Tian Y; Zhang Z; Xiang Z; Wang H; Guo J; Xiao GG
Dig Dis Sci; 2024 Apr; 69(4):1263-1273. PubMed ID: 38451429
[TBL] [Abstract] [Full Text] [Related]
5. A case report of carcinoma of the papilla of Vater associated with a hyperplasia-dysplasia-carcinoma sequence by pancreaticobiliary maljunction.
Korai T; Kimura Y; Watanabe K; Low SK; Imamura M; Nagayama M; Kukita K; Murakami T; Kato T; Kondo Y; Kyuno D; Sugawara T; Murota A; Kawakami Y; Masaki Y; Nakase H; Takemasa I
World J Surg Oncol; 2024 Feb; 22(1):63. PubMed ID: 38389074
[TBL] [Abstract] [Full Text] [Related]
6. New ceaCAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.
Jancewicz I; Śmiech M; Winiarska M; Zagozdzon R; Wisniewski P
Cancer Immunol Immunother; 2024 Jan; 73(2):30. PubMed ID: 38279989
[TBL] [Abstract] [Full Text] [Related]
7. CA19-9 and cea biosensors in pancreatic cancer.
Ahmadipour M; Bhattacharya A; Sarafbidabad M; Syuhada Sazali E; Krishna Ghoshal S; Satgunam M; Singh R; Rezaei Ardani M; Missaoui N; Kahri H; Pal U; Ling Pang A
Clin Chim Acta; 2024 Feb; 554():117788. PubMed ID: 38246211
[TBL] [Abstract] [Full Text] [Related]
8. The emerging roles of ceaCAM6 in human cancer (Review).
Wu G; Wang D; Xiong F; Wang Q; Liu W; Chen J; Chen Y
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240103
[TBL] [Abstract] [Full Text] [Related]
9. Revisiting the performance of cyst fluid carcinoembryonic antigen as a diagnostic marker for pancreatic mucinous cysts: a comprehensive 20-year institutional review.
Kwan MC; Pitman MB; Fernandez-Del Castillo C; Zhang ML
Gut; 2024 Mar; 73(4):629-638. PubMed ID: 38195219
[TBL] [Abstract] [Full Text] [Related]
10. Serum cea as a Prognostic Marker for Overall Survival in Patients with Localized pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study.
Doppenberg D; Stoop TF; van Dieren S; Katz MHG; Janssen QP; Nasar N; Prakash LR; Theijse RT; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B; Besselink MG;
Ann Surg Oncol; 2024 Mar; 31(3):1919-1932. PubMed ID: 38170408
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic Effect of Preoperative Inflammatory Markers on Morbidity and Overall Survival in pancreatic Adenocarsinoma.
Çaparlar MA; Durhan A; Süleymanov M; Binarbaşı C; Koşmaz K
Niger J Clin Pract; 2023 Dec; 26(12):1902-1909. PubMed ID: 38158359
[TBL] [Abstract] [Full Text] [Related]
12. Development and characterization of NILK-2301, a novel ceacam5xCD3 κλ bispecific antibody for immunotherapy of ceacam5-expressing cancers.
Seckinger A; Majocchi S; Moine V; Nouveau L; Ngoc H; Daubeuf B; Ravn U; Pleche N; Calloud S; Broyer L; Cons L; Lesnier A; Chatel L; Papaioannou A; Salgado-Pires S; Krämer S; Gockel I; Lordick F; Masternak K; Poitevin Y; Magistrelli G; Malinge P; Shang L; Kallendrusch S; Strein K; Hose D
J Hematol Oncol; 2023 Dec; 16(1):117. PubMed ID: 38087365
[TBL] [Abstract] [Full Text] [Related]
13. A novel human single-domain antibody-drug conjugate targeting ceacam5 exhibits potent in vitro and in vivo antitumor activity.
Zhu XY; Li QX; Kong Y; Huang KK; Wang G; Wang YJ; Lu J; Hua GQ; Wu YL; Ying TL
Acta Pharmacol Sin; 2024 Mar; 45(3):609-618. PubMed ID: 38030799
[TBL] [Abstract] [Full Text] [Related]
14. Glucose and lactate levels are lower in EUS-aspirated cyst fluid of mucinous vs non-mucinous pancreatic cystic lesions.
Rossi G; Petrone MC; Tacelli M; Zaccari P; Crippa S; Belfiori G; Aleotti F; Locatelli M; Piemonti L; Doglioni C; Falconi M; Capurso G; Arcidiacono PG
Dig Liver Dis; 2024 May; 56(5):836-840. PubMed ID: 38008697
[TBL] [Abstract] [Full Text] [Related]
15. Neoadjuvant chemotherapy for borderline resectable colorectal cancer liver metastases: a single-institution retrospective study.
Kitano Y; Ono Y; Kobayashi K; Oba A; Sato T; Ito H; Inoue Y; Shinozaki E; Yamaguchi K; Saiura A; Baba H; Takahashi Y
HPB (Oxford); 2024 Feb; 26(2):282-290. PubMed ID: 37985325
[TBL] [Abstract] [Full Text] [Related]
16. Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: the CHAMP study.
Hau SO; Svensson M; Petersson A; Eberhard J; Jirström K
BMC Cancer; 2023 Nov; 23(1):1074. PubMed ID: 37936126
[TBL] [Abstract] [Full Text] [Related]
17. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm.
Cui M; Hu Y; Zhang Z; Chen T; Dai M; Xu Q; Guo J; Zhang T; Liao Q; Yu J; Zhao Y
Signal Transduct Target Ther; 2023 Oct; 8(1):406. PubMed ID: 37848412
[TBL] [Abstract] [Full Text] [Related]
18. [Heterogeneity analysis of pancreatic cancer and identification of molecular subtypes of tumor cells based on ceacam5, LGALS1 and CENPF gene expression].
Sun J; Lu P; Guan S; Liu S
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Sep; 43(9):1567-1576. PubMed ID: 37814871
[TBL] [Abstract] [Full Text] [Related]
19. EUS-guided fine needle aspiration-based clues to mistaken or uncertain identity: serous pancreatic cysts.
Yip-Schneider MT; Muraru R; Kim RC; Wu HH; Sherman S; Gutta A; Al-Haddad MA; Dewitt JM; Schmidt CM
HPB (Oxford); 2023 Dec; 25(12):1587-1594. PubMed ID: 37749004
[TBL] [Abstract] [Full Text] [Related]
20. Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma.
Boyev A; Prakash LR; Chiang YJ; Newhook TE; Bruno ML; Arvide EM; Dewhurst WL; Kim MP; Ikoma N; Lee JE; Snyder RA; Tzeng CD; Katz MHG; Maxwell JE
Surg Oncol; 2023 Dec; 51():101994. PubMed ID: 37742542
[TBL] [Abstract] [Full Text] [Related]
[Next]
